Acquisitions in the biotech and pharmaceutical sectors, especially those that enhance a company's product lineup in high-demand areas like oncology, are often viewed positively by the market. This acquisition could lead to increased investor confidence in Genmab's growth prospects, potentially driving up its stock price in the short term.